MicroPort Scientific Corporation (the "Company") consists of two geographically distinctive operational business units: Greater China and Intercontinental respectively managed by Greater China Executive Committee ("CEC") and Intercontinental Executive Committee ("IEC").
- Dr. Zhaohua ChangExecutive Director
Dr. Zhaohua Chang is the Chairman and Chief Executive Officer of the Company. He has over 27 years' experience in the medical device industry. Dr. Chang studied at the Shanghai Institute of Mechanical Engineering from 1979 to 1987 toward his bachelor, master and doctoral degrees in Engineering. In 1992, Dr. Change achieved his doctoral degree in Biological Science at the State University of New York. Dr. Chang worked as Director, and subsequently Vice President, of Research and Development of Cryomedical Sciences between 1990 and 1995. Dr. Chang was the Vice President of Research and Development of Endocare Inc., a NASDAQ listed medical device company based in California, from 1996 to 1997. He has published extensively in biomedical fields and holds many patents.
- Norihiro AshidaNon-executive Director
Mr. Norihiro Ashida, born in 1954, is a Non-executive Director of our Company. Mr. Ashida has served as a Director since 1 November 2006 and has also served as a Director of MP Shanghai since March 2004. Mr. Ashida is currently holding directorship in certain subsidiaries of the Group. Mr. Ashida is an Executive Operating Officer of Otsuka Holdings Co., Ltd. ("Otsuka Holdings") and the Director of its corporate development department. Mr. Ashida is also a Director of Otsuka Medical Devices Co., Ltd. He joined Otsuka Pharmaceutical Co., Ltd. ("Otsuka Pharmaceutical") in April 2003 from Mizuho Corporate Bank Ltd., where he was a general manager from 2002 to 2003. From 1999 to 2002, Mr. Ashida was a general manager of the Industrial Bank of Japan ("IBJ"), where he headed the credit department for western Japan. From 1995 to 1999, Mr. Ashida served as Vice President responsible for business development at 3iBJ Ltd., a venture capital firm formed by 3i Group plc and IBJ. From 1989 to 1995, Mr. Ashida was a Senior Vice President of IBJ (Canada). He joined IBJ in 1977 in its Tokyo branch. Mr. Ashida received his bachelor's degree in economics from the University of Tokyo in 1977.
- Hiroshi ShirafujiNon-executive Director
Mr. Hiroshi Shirafuji, born in 1944, is a non-executive Director of our Company. Mr. Shirafuji has served as a Director since 1 November 2006 and is also a director of certain subsidiaries of the Group. Mr. Shirafuji is the President of Otsuka Medical Devices Co., Ltd. ("OMD"), a subsidiary of Otsuka Holdings Co., Ltd. ("Otsuka Holdings"). Prior to joining OMD in February 2011, he was an executive director responsible for pharmaceuticals marketing at Otsuka Pharmaceutical from 1997 to 1998. Mr. Shirafuji joined Otsuka Pharmaceutical in 1967. Mr. Shirafuji received his bachelor's degree in economics from Doshisha University in Kyoto in 1967. Mr. Shirafuji was also appointed as President and CEO, representative director of Otsuka Medical Devices Co., Ltd. in February 2011.
- Weiwei ChenNon-executive Director
Ms. Weiwei Chen, born in 1972, was appointed as the Non-executive Director of the Company on 30 June 2014. Ms. Weiwei Chen is also a director of Shanghai Medical Devices (Group) Co., Ltd, Leader City Limited and MicroPort Medical Limited (other members of the Company). Ms. Weiwei Chen is now the Deputy Chief Economist and Manager of Investment Management Department of Shanghai Zhangjiang (Group) Co., Ltd. Ms. Weiwei Chen graduated from Tongji University with a master degree in Environment Engineering. Ms. Chen, an economist, has the senior qualification of China Association for Professional Managers and the professional title of Engineer.
- Junyuan FengNon-executive Director
Ms. Junyuan Feng, born in 1969, was appointed as MicroPort®'s Non-executive Director on 29 March 2016. She is currently a managing director of the Carlyle Group. Ms. Feng has been involved in many direct investments by the Carlyle Group in consumer, financial, and industrial companies in the PRC. Prior to joining the Carlyle Group, Ms. Feng worked for Credit Suisse First Boston's New York office, engaging in investment banking business. She was a non-executive director of China Pacific Insurance (Group) Co., Ltd. from 2007 to 2013, a non-executive director of Natural Beauty Bio-Technology Limited from 2009 to 2014, and a non-executive director of Haier Electronics Group Co., Ltd. from 2011 to 2015. Ms. Feng has also served as an alternate director in China Fishery Group Limited from 2010 to 2015. Ms. Feng is currently serving as a non-executive director of Hedy Holding Company Limited, and a non-executive director of Meinian Onehealth Healthcare (Group) Co., Ltd. Ms. Feng received a Master of Business Administration degree from Harvard Business School and a Bachelor of Arts degree from Middlebury College.
- Jonathan H. ChouIndependent Non-executive Director
Mr. Jonathan H. Chou, born in 1964, was appointed as our Independent Non-executive Director on 3 September 2010. Mr. Chou has served as Senior Vice President & Chief Financial Officer of Kulicke&Soffa Industries, Inc., a NASDAQ listed company (NASDAQ: KLIC) since December 2010. After successful completion of the move of Kulicke&Soffa's Global Corporate Headquarters from the U.S. to Singapore, he led a complex business tax restructuring project to improve operating efficiency and reduce the company's effective tax rate during a record setting fiscal year of 2011. Effective October 1, 2012, Mr. Chou's overall responsibilities expanded to include Global Information Technology. Mr. Chou has over 20 years of professional experience largely with Fortune 500 companies. He was the Asia Pacific Chief Financial Officer and Vice President, Mergers & Acquisitions of Honeywell International, where he managed the company's M&A activities in the region from Shanghai, China. Prior to Honeywell, he was the Asia Chief Financial Officer of Tyco ADT, the Fire & Security segment of Tyco International, where he led initiatives to improve operating efficiency and improvement of corporate governance to meet Sarbanes-Oxley attestation. Mr. Chou served as Asia/Pacific Regional Chief Financial Officer of Lucent Technologies Inc., based in Hong Kong and Singapore. Before that, he held the position of Managing Director of Treasury & Customer Finance for Asia Pacific and China regions, with a portfolio of over $1.4 billion of vendor financing commitments. Prior to joining K&S, Mr. Chou was the Chief Financial Officer of a private equity portfolio company, where he was instrumental in managing the audit and listing process. In April 2009, he was awarded "China's Top Ten CFOs of 2008" by CFO World Magazine in recognition of his leadership role for navigating through the global financial crisis. Mr. Chou received a Bachelor of Arts degree from the State University of New York at Buffalo in 1988 and a master's degree in business administration from Fuqua School of Business at Duke University in 1999.
- Dr. Guoen LiuIndependent Non-executive Director
Dr. Guoen Liu, born in 1957, was appointed as our Independent Non-executive Director on 3 September 2010. Dr. Liu is a noted scholar in the fields of health and development economics, health reform and pharmaceutical economics. Dr. Liu has served as professor of economics at Guanghua School of Management of Peking University, executive director of the Guanghua School of Management Health Economics and Management Institute of Peking University, and director of the China Center for Pharmaceutical Economics and Outcomes Research of Peking University since 2006. From 2000 to 2006, Dr. Liu was tenured associate professor of University of North Carolina at Chapel Hill. From 1994 to 2000, Dr. Liu was assistant professor of University of Southern California. Dr. Liu also serves as editor or a member of the editorial board in various periodic in the field of pharmaceutical economics. Dr. Liu received his bachelor's degree in mathematics from Southwestern University for Nationalities in 1981, his master's degree in statistics from Southwestern University of Finance and Economics in 1985, his Ph.D. in economics from the City University of New York in 1991, and post-doctoral training in health economics from Harvard University in 1994.
- Chunyang ShaoIndependent Non-executive Director
Mr. Chunyang Shao was appointed as the Independent Non-executive Director on 23 September, 2016. Mr. Shao is currently a partner of JunHe LLP and a member of the All China Lawyers Association and Shanghai Bar Association. Mr. Shao specializes in corporate, foreign investment, real estate, mergers and acquisitions, securities, infrastructure and project finance. From July 1988 to October 1993, Mr. Shao worked in Anhui Foreign Economy Law Office. From November 1995 to March 2002, Mr. Shao worked in the London, Hong Kong and China offices of major international law firms of Simmons & Simmons as Chinese legal counsel and Sidley Austin as a senior legal consultant. Mr. Shao joined JunHe LLP in April 2002. Mr. Shao is currently the independent director of Changjiang & Jinggong Steel Building (Group) Co., Ltd. ( 长江精工钢结构( 集团) 股份有限公司), a company listed on Shanghai Stock Exchange (stock code: 600496). Mr. Shao received his bachelor degree in law from East China University of Political Science and Law in 1987, and was admitted to practice PRC law in 1988. From 1993 to 1994, Mr. Shao worked as visiting lawyer in Sino-Britain Young Lawyers' Exchange Program in the UK. In 2002, he received his master degree in law from East China University of Political Science and Law.
Last Updated: September, 2016